Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Disease area: Airway diseases, Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Kulichenko, L. Namasova, O. Lukina, R. Torshkhoeva, E. Vishneva (Moscow, Russian Federation). Omalizumab in children with severe persistent allergic asthma. Eur Respir J 2010; 36: Suppl. 54, 2633

Member's Comments

No comment yet.

Related content which might interest you: Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017 Omalizumab, a novel therapy for severe allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001 Omalizumab in severe adult atopic dermatitis associated to mild asthma treated with omalizumab Source: Annual Congress 2012 - Asthma: assessment and treatment Year: 2012 Immunotherapy in severe asthma Source: ERS webinar 2021: Immunotherapy in severe asthma Year: 2021 Omalizumab decreases IgE production in patients with severe allergic asthma Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012 Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009 Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2002; 20: 73-78 Year: 2002 Efficacy of montelukast in patients with concomitan persistent allergic rhinitis and asthma Source: Eur Respir J 2006; 28: Suppl. 50, 663s Year: 2006 IL-33 in patients with severe uncontrolled allergic asthma Source: International Congress 2017 – "Alarming" immunological patterns in asthma Year: 2017 Early-onset allergic severe asthma Source: International Congress 2015 – Severe asthma phenotyping Year: 2015 Real-life long-term omalizumab therapy in children with severe allergic asthma Source: Eur Respir J 2015; 46: 856-859 Year: 2015 The march from subclinical small-airways dysfunction to asthma in children with allergic rhinitis Source: International Congress 2019 – Severe acute asthma and troublesome wheezing Year: 2019 Dupilumab efficacy in children with uncontrolled, moderate-to-severe asthma with and without an allergic phenotype Source: Virtual Congress 2021 – Advances in childhood asthma: biologics, biomarkers and infections Year: 2021 The evaluations of allergic rhinitis symptoms in patients with asthma and allergic rhinitis with the addiing of montelukast in asthma treatment Source: Eur Respir J 2004; 24: Suppl. 48, 124s Year: 2004 Omalizumab is effective in patients with severe persistent allergic asthma in a real-life setting irrespective of age Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Assesment of long-term omalizumab treatment in severe allergic asthma Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia Source: Eur Respir J 2014; 44: 239-241 Year: 2014 Immunotherapy prevents the development of asthma in subjects with allergic rhinitis Source: Eur Respir J 2001; 18: Suppl. 33, 482s Year: 2001 Diagnosis and treatment of allergic rhinitis in asthmatic children Source: Annual Congress 2009 - Allergic rhinitis and its impact on asthma in children Year: 2009